ID27487A - Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat - Google Patents

Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat

Info

Publication number
ID27487A
ID27487A IDW20001981A ID20001981A ID27487A ID 27487 A ID27487 A ID 27487A ID W20001981 A IDW20001981 A ID W20001981A ID 20001981 A ID20001981 A ID 20001981A ID 27487 A ID27487 A ID 27487A
Authority
ID
Indonesia
Prior art keywords
dioxoethyl
phenylmethyl
indol
acetate
ethyl
Prior art date
Application number
IDW20001981A
Other languages
English (en)
Indonesian (id)
Inventor
William L Confer
Hideaki Tai
Original Assignee
Shionolog & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionolog & Co Ltd filed Critical Shionolog & Co Ltd
Publication of ID27487A publication Critical patent/ID27487A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IDW20001981A 1998-03-03 1999-03-02 Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat ID27487A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7665998P 1998-03-03 1998-03-03

Publications (1)

Publication Number Publication Date
ID27487A true ID27487A (id) 2001-04-12

Family

ID=22133426

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001981A ID27487A (id) 1998-03-03 1999-03-02 Komposisi farmasi yang mengandung penghambat fosfolipase natrium (3-(2-amino-1,2-dioksoetil)-2-etil-1-fenilmetil) 1h-indol-4) oksi) asetat

Country Status (21)

Country Link
US (1) US6166062A (de)
EP (1) EP1058547B1 (de)
JP (3) JP2002505282A (de)
KR (1) KR20010034552A (de)
CN (1) CN1299277A (de)
AT (1) ATE310513T1 (de)
AU (1) AU757002B2 (de)
BR (1) BR9908479A (de)
CA (1) CA2322796A1 (de)
DE (1) DE69928500T2 (de)
EA (1) EA003864B1 (de)
ES (1) ES2253877T3 (de)
HU (1) HUP0102812A3 (de)
ID (1) ID27487A (de)
IL (1) IL138154A0 (de)
NO (1) NO20004306L (de)
NZ (1) NZ506578A (de)
PL (1) PL342822A1 (de)
TR (1) TR200002543T2 (de)
TW (1) TW570795B (de)
WO (1) WO1999044604A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001055108A2 (en) * 2000-01-25 2001-08-02 Eli Lilly And Company Use of spl a2 inhibitors for the treatment of inflammation
EP1265607A2 (de) * 2000-03-09 2002-12-18 Eli Lilly And Company BEHANDLUNG DER RENALEN DYSFUNKTION MIT sPLA2-INHIBITOREN.
EP1303262A2 (de) * 2000-07-14 2003-04-23 Eli Lilly And Company Verwendung eines spla2-hemmers zur behandlung von sepsis
TWI232102B (en) 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
US20050250738A1 (en) * 2004-05-06 2005-11-10 Mosher Gerold L Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
ATE517619T1 (de) * 2006-06-09 2011-08-15 Ucb Pharma Gmbh Stabilisierte pharmazeutische zusammensetzung mit fesoterodin
CA2677831A1 (fr) * 2007-02-12 2008-08-21 Lassaad Boujbel Le sucralose solution sterile sans conservateurs
JP5174365B2 (ja) * 2007-03-23 2013-04-03 第一三共株式会社 キノロン含有凍結乾燥製剤の製造方法
EP2106788A1 (de) * 2008-04-04 2009-10-07 Ipsen Pharma Flüssige und lyophilisierte Formulierungen
ES2968301T3 (es) 2008-08-05 2024-05-08 Wyeth Llc Liofilización por encima del colapso
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR20140053952A (ko) * 2011-08-26 2014-05-08 제이더블유중외제약 주식회사 피라지노-트리아진 유도체를 포함하는 조성물
EP2923710A1 (de) 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bakterielle Phospholipase-Inhibitoren als Modulatoren von Dickdarmbakterienflora

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873860L (no) * 1986-10-31 1988-05-02 Asta Pharma Ag Ifosfamid-lyofilisat og fremgangsmaate til deres fremstilling.
JPH02207092A (ja) * 1989-02-07 1990-08-16 Kirin Brewery Co Ltd アンスラサイクリン化合物またはその塩の凍結乾燥製剤の製造法
ATE187071T1 (de) * 1993-10-27 1999-12-15 Upjohn Co Stabilisiertes prostaglandin e1
JP3109974B2 (ja) * 1994-04-01 2000-11-20 イーライ・リリー・アンド・カンパニー 1H−インドール−3−グリオキシルアミドsPLA2阻害剤

Also Published As

Publication number Publication date
IL138154A0 (en) 2001-10-31
CA2322796A1 (en) 1999-09-10
HUP0102812A3 (en) 2002-01-28
TW570795B (en) 2004-01-11
EA200000897A1 (ru) 2001-02-26
US6166062A (en) 2000-12-26
AU2799899A (en) 1999-09-20
ATE310513T1 (de) 2005-12-15
HUP0102812A2 (hu) 2001-12-28
TR200002543T2 (tr) 2000-11-21
WO1999044604A1 (en) 1999-09-10
JP2011021042A (ja) 2011-02-03
EP1058547B1 (de) 2005-11-23
AU757002B2 (en) 2003-01-30
DE69928500T2 (de) 2006-08-03
WO1999044604A9 (en) 2000-01-20
NO20004306L (no) 2000-10-10
JP2002505282A (ja) 2002-02-19
NZ506578A (en) 2003-09-26
JP2006096761A (ja) 2006-04-13
EP1058547A1 (de) 2000-12-13
BR9908479A (pt) 2000-12-05
ES2253877T3 (es) 2006-06-01
KR20010034552A (ko) 2001-04-25
PL342822A1 (en) 2001-07-02
NO20004306D0 (no) 2000-08-29
DE69928500D1 (de) 2005-12-29
CN1299277A (zh) 2001-06-13
EA003864B1 (ru) 2003-10-30

Similar Documents

Publication Publication Date Title
NO20004306L (no) Farmasøytiske sammensetninger som inneholder fosfolipaseinhibitoren natrium[[3-(2-amino-1,2-dioksoetyl-1- fenylmetyl)-1H-indol-4-yl]oksy)acetat
BR0008405A (pt) Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
YU20194A (sh) 1H-INDOL-3-ACETAMIDI KAO INHIBITORI s PLA2
EA200000433A1 (ru) Комбинация ингибитора альдозоредуктазы и ингибитора гликогенфосфорилазы
BR0016555A (pt) Composições farmacêuticas que proporcionam concentrações acrescidas de droga
ES2157684T3 (es) Composicion de blanqueo de la piel y/o de los cabellos.
HUP0300850A2 (hu) Gyűrűs béta-aminosav-származékok mint mátrix metalloproteázok és a TNF-alfa inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
UY27320A1 (es) Nuevas composiciones farmacéuticas
PE84899A1 (es) Formulaciones farmaceuticas que contienen voriconazol
EA199901100A1 (ru) Фармацевтические композиции, содержащие гемисульфат элетриптана и кофеин
AR034226A2 (es) Procedimiento perfeccionado para estabilizar proteinas.
BR9714061A (pt) Composições antitraspirantes em bastão de gel sólido contendo composições antitranspirante em bastão de gel sólido contendo agentes nucleantes selecionados.
GEP20115348B (en) Pharmaceutical composition for treating burns (variants) and methods for the production thereof (variants)
RU2016118646A (ru) Стабильные водные композиции белка MIA/CD-RAP
BG102383A (bg) Антимикробни състави,съдържащи с долу 3-с долу 6алкохол
BRPI0407652A (pt) método para acentuar a eficácia de um agente ativo, composição e método para produzir a composição
AR039123A1 (es) Composicion farmaceutica estable que contiene el factor viii
EE05054B1 (et) 5-HT4 agonisti v?i antagonisti peroraalne ravimkoostis ja selle kasutamine meditsiinis
NO20042459L (no) Vannbasert farmasoytiske formuleringer av vannloselige prodrug av propofol
EA200300406A1 (ru) Фармацевтическая композиция дронедарона для парентерального введения
PT769951E (pt) Composicao de oxitetraciclina de longa accao
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
TR200100611T2 (tr) İbuprofen ve domperidon içeren farmasötik kompozisyonlar
DE69819900D1 (de) Wässrige flüssige pharmazeutische zusammensetzung enthaltend ein benzopyranderivat als hauptbestandteil